Main contents starts here
Press Releases 2007
- December 18, 2007
Lu AA21004 for the treatment of mood and anxiety disorders enters into clinical phase III - December 18, 2007
Takeda Submitted an Application for an Additional Indication of BASEN® in Japan for Prevention of Onset of Type 2 Diabetes in Patients with Impaired Glucose Tolerance - November 20, 2007
Takeda to Sponsor the 61st Fukuoka International Open Marathon Championship, 2007 - November 19, 2007
Takeda Established a New Company in the U.S. for Therapeutic Antibody Research - November 9, 2007
The Results of HIJ-CREATE Study, a Large-scaled Clinical Study of Candesartan with Coronary Artery Disease Patients with Hypertension in Japan - November 6, 2007
Affymax® Announces Hematide™ Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (Prca)
-- Phase 2 Study Findings Presented at American Society of Nephrology Renal Week 2007 -- - November 5, 2007
Takeda's Investigational Compound TAK-442 for Treatment of Venous/Arterial Thromboembolism Enters into Phase 2 Clinical Stage in the U.S. and Europe - November 5, 2007
Notice regarding Revision to Increase Interim and Planned Annual Dividends for the Fiscal Year Ending March 31, 2008 - November 1, 2007
Transfer of Shares of Sumitomo Chemical Takeda Agro Company, Ltd. from Takeda to Sumitomo Chemical - October 29, 2007
Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholesterolemia - October 24, 2007
Lu AA24530 for the treatment of mood and anxiety disorders enters into clinical phase II - October 19, 2007
Affymax® and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide™ for Anemia - October 12, 2007
Affymax Doses First Patient in The Phase 3 Clinical Program of Hematide™ to Treat Anemia in Chronic Renal Failure Patients - October 1, 2007
Transfer of Shares of House Wellness Foods Corporation from Takeda to House Foods - September 21, 2007
Takeda to Sponsor Berlin Marathon 2007 - September 5, 2007
Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders - September 4, 2007
Takeda Settles a Lawsuit over Remuneration for Employee Invention Regarding an Anti-prostate Cancer and Anti-endometriosis Drug, Leuplin® - August 30, 2007
Notice of Execution of Acquisition of the Company's Own Shares - August 30, 2007
Lilly and Takeda to Terminate Joint Development/Co-Marketing Agreement on Ruboxistaurin mesylate, an agent for the treatment of diabetes microvascular complications - August 30, 2007
Takeda’s Investigational Compound TAK-536 for Treatment of Hypertension Enters into Phase 2 Clinical Stage in Japan - August 24, 2007
Approval of an additional dosage and administration for secondary eradication of Helicobacter pylori for proton pump inhibitors in Japan - August 17, 2007
European EMEA acceptance of Marketing Authorization Application filing for SNT-MC17 in Friedreich’s Ataxia by Santhera - August 2, 2007
Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy - August 1, 2007
Takeda to License CCR5 Antagonists for Treatment of HIV Infection to Tobira Therapeutics, Inc. - July 31, 2007
Ajinomoto and Takeda submits Additional Indication for Paget's Disease of Bone for Risedronate Sodium Hydrate designated as Orphan Drug - July 31, 2007
Notice regarding Acquisition of the Company's own shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - July 31, 2007
Takeda Responds to the FDA Advisory Committee Recommendation - July 19, 2007
Takeda's Investigational Compound TAK-491 for Treatment of Hypertension Enters into Phase 3 Clinical Stage in the U.S. and Europe - July 12, 2007
Sucampo Pharmaceuticals Submits Supplemental New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation - July 2, 2007
Takeda Wins Patent Infringement Litigation on Appeal against ANDA Filers for Generic ACTOS® - June 27, 2007
Submission of an Application for an additional Indication of Actos® in Japan; Concomitant Therapy with Insulin for Type 2 Diabetes - June 26, 2007
Notice of Execution of Acquisition of the Company's Own Shares - June 15, 2007
Takeda Launched Once-a-week Formulation of Benet®17.5mg tablet for the Treatment of Osteoporosis in Japan - June 11, 2007
Archemix and Takeda to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics - June 1, 2007
Termination of Development of Fixed Dose Combination Product of Actos® + TAK-536
Takeda is continuously committed to provide novel treatment options in cardiovascular/diabetes franchises - May 30, 2007
Biowa and Takeda Announce Licensing of Biowa's Potelligent® Technology for Use in Antibody Research and Development - May 24, 2007
Approval of an Additional Indication of Combination Therapy of Glufast® and Alpha-glucosidase Inhibitor in Japan - May 18, 2007
Notice about Partial Amendments to the Articles of Incorporation - May 18, 2007
Notice regarding Acquisition of the Company's Own Shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - May 16, 2007
Takeda to Revise Retirement Plan - May 10, 2007
Notice about Election of Accounting Auditor - May 7, 2007
Official Completion of New Patient Enrollment of Post Marketing Surveillance on Enbrel Shows Encouraging Results for Patients and Physicians - April 26, 2007
Takeda to Transfer its Business of Leasing of Office Building to the Consolidated Subsidiary by Corporate Demerger - April 23, 2007
Application for an Additional Indication of Combination Therapy of Glufast® and Insulin Sensitizer in Japan - April 18, 2007
AFFYMAX® AND TAKEDA HONORED WITH THE ALLICENSE 2007 BREATKTHROUGH ALLIANCE AWARD FOR THEIR EXCLUSIVE GLOBAL AGREEMENT FOR HEMATIDE™ - April 13, 2007
TAKEDA to Start the Global Leadership Training Program - March 30, 2007
LG Life Sciences and Takeda Announce Collaboration for Anti-Obesity Drugs - March 30, 2007
CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer - March 30, 2007
Takeda to Obtain Development and Commercial Rights for R-851 from 3M
Investigational Compound for the Treatment for Cervical High-Risk HPV Infection - March 26, 2007
Attorney's Fees Reimbursement granted in Takeda's Patent case on ACTOS® - March 20, 2007
Takeda's New Structure for Pharmaceutical Marketing Division in Japan - March 20, 2007
Takeda Submits a European Marketing Authorization Application for Ramelteon, a New Treatment for Insomnia - March 12, 2007
Takeda to Acquire Paradigm Therapeutics - February 28, 2007
XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development - January 31, 2007
In-kind Contribution of Shares of European Subsidiaries to Takeda Europe Holdings B.V. - January 31, 2007
Merger of Three Consolidated Subsidiaries, Daiwa Estate, Shinwa Estate and Takeda Pharmaceutical Real Estate - January 18, 2007
Submission of an Application for an additional Indication of Actos® in Japan; Concomitant Therapy with Biguanides for Type 2 Diabetes - January 17, 2007
Marketing Authorisation Granted for Tandemact™ (pioglitazone/glimepiride) for Type 2 Diabetes in Europe